Retour au classement

iRhythm Technologies, Inc. (IRTC)

Juste valeur
HealthcareMedical DevicesUnited States

Fondamental

43

Prix

$111.51

Capitalisation boursière

$3.75B

Partie 1 · Ce que vaut l'entreprise

Vue d'ensemble

iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 18 septembre 2026 with claude-haiku-4-5 — shared with all users

P/E: 17.7Score: 73Market cap: $63.93B

Its Preventice Solutions arm, acquired for $925 million, is the closest challenger to Zio in long-term continuous ECG patch monitoring in the United States.

P/E: —Score: 51Market cap: $12.14B

Baxter owns Bardy Diagnostics, whose Carnation ambulatory monitor patch is prescribed for the same arrhythmia work-ups that Zio is used for.

P/E: 15.7Score: 56Market cap: $30.20B

GE HealthCare supplies the traditional 24-to-48-hour Holter monitors that hospitals and clinics can choose instead of sending a patient home with a Zio patch.

Koninklijke Philips N.V. (Royal Philips)PHG

Through BioTelemetry, which it bought for $2.8 billion, Philips sells the wearable ECG patches and mobile cardiac telemetry services that compete directly with iRhythm's Zio for the same cardiologists and the same insurance reimbursement.

Medtronic plcMDT

Medtronic's LINQ family of insertable cardiac monitors targets the same patients under investigation for atrial fibrillation and unexplained fainting, competing for the diagnostic referral before a Zio is ever prescribed.

VitalConnect, Inc.Not tracked

This private US company sells the VitalPatch, a disposable ECG patch with AI arrhythmia detection sold to the same cardiology practices that buy Zio.

Bilan & Liquidités

Chiffre d'affaires

$825M

12 derniers mois (au 30/06/2026)

Résultat net

$-14M

12 derniers mois (au 30/06/2026)

Flux de trésorerie libre

$35M

Capitaux propres totaux

$153M

Passif total

$867M

Ratio de liquidité général

3.85

Couverture des intérêts

1.89

Dette/EBITDA

-

Bénéfice par action

Chiffre d'affaires & Résultat net

Flux de trésorerie libre

Décomposition du résultat

État historique

Marges dans le temps

La dette dans le temps

Le poids de la dette

Grille de la croissance

Croissance — Chiffre d'affaires

Estimation de la juste valeur

Cas généralJustement valorisé

Juste valeur

$104.37

Prix actuel

$111.51

Marge de sécurité

-6.8%

Fourchette de juste valeur

$67.84 - $140.89

Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.

Méthodes d'estimation

Objectif de cours des analystes:$176.14
Flux de trésorerie actualisés (DCF):$14.64
Multiple de résultat (P/E):Données insuffisantes pour le calculer
Formule de croissance de Graham:Données insuffisantes pour le calculer
Valeur de la capacité bénéficiaire (EPV):Données insuffisantes pour le calculer
P/B justifié:Données insuffisantes pour le calculer
Actualisation des dividendes (Gordon):Données insuffisantes pour le calculer
P/FFO, les fonds provenant de l'exploitation:Données insuffisantes pour le calculer
Bénéfices de milieu de cycle:Données insuffisantes pour le calculer
Multiple sur le chiffre d'affaires:$98.85
Consensus des analystes:Achat fort (20B / 1H / 0S)
Dernière surprise sur les résultats:+12988.89%

Indicateurs de valorisation

Ratio P/E

-

ROE

-29.2%

Ratio P/B

20.14

P/FCF

96.12

Marge brute

71.5%

ROIC

-2.2%

Radar de rentabilité

Création de valeur (avantage concurrentiel)

ROIC

-2.2%

WACC

10.5%

ROIC − WACC

-12.7 pp

Le ROIC est inférieur au coût du capital — l'entreprise détruit de la valeur pour chaque dollar investi.

Critères d'analyse fondamentale

Réussi (12)

  • EPS shows upward trend
  • Price CAGR 14.06%
  • Gross Margin 71.5%
  • Positive Free Cash Flow
  • Current Ratio
  • Interest Coverage
  • Low reliance on intangibles
  • Revenue Growth 5Y 23.0%
  • Analyst Consensus 95% Buy
  • Earnings Surprise avg 3463.2%
  • Net Margin Trend -1.7% vs -14.1%
  • Piotroski F-Score 6/9

Échoué (10)

  • ROIC -2.2%
  • P/FCF 96.12
  • P/B Ratio 20.14
  • Debt/Equity ratio
  • Operating Margin -3.0%
  • CapEx intensity
  • Return on Tangible Assets
  • DCF valuation (Overvalued)
  • ROE -9.0%
  • Share Dilution 2.7%

Indisponible (5)

  • Dividend Payout NaN%
  • Debt/EBITDA
  • Price below Graham Number
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)

Score F de Piotroski

6/9

Signaux mixtes : certains domaines nécessitent attention

score
criteria

Qualité des bénéfices

-

Qualité faible : examiner la comptabilité

Dilution du capital

2.7%

Émission de nouvelles actions, diluant la participation

Participations institutionnelles

Gouvernance

Équipe dirigeante

NomTitreÂge
Mr. Quentin S. BlackfordPresident, CEO & Director46
Mr. Daniel G. WilsonCFO & Principal Financial Officer43
Dr. Minang P. Turakhia M.D., M.S.Chief Medical & Scientific Officer and Executive VP of Advanced Technologies51
Mr. Patrick Michael Murphy J.D.Chief Business & Legal Officer46
Mr. Chad M. PattersonChief Commercial and Product Officer43
Mr. Mervin SmithExecutive Vice President of Business Operations50
Mr. Marc RosenbaumSenior VP of Finance & Chief Accounting Officer52
Mr. Brian LawrenceExecutive VP & CTO55
Ms. Lisa PecoraSenior Vice President of Finance & Investor Relations-
Mr. Sean Clinton FreemanExecutive Vice President of Strategy & Corporate Development49

Risque d'audit

9

Risque du conseil

5

Risque de rémunération

3

Risque droits des actionnaires

7

Partie 2 · Le prix et le moment d'entrer

Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.

Documents

  • Rapport annuel (10-K)

    Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.

    Déposé le 2026-02-19

    Voir le document
  • Rapport trimestriel (10-Q)

    Une mise à jour de la performance financière des trois derniers mois.

    Déposé le 2026-08-06

    Voir le document
  • Rapport d'événement important (8-K)

    Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.

    Déposé le 2026-09-22

    Voir le document

via SEC EDGAR

Historique des résultats

via SEC EDGAR

Latest News

Recent headlines for IRTC, sourced from Markets Gazette.

  • 3d agoPOSITIVE
    JP Morgan forecasts a 20x revenue increase for this AI stock

    JP Morgan has significantly boosted its outlook for US-listed iRhythm Technologies Inc. (IRTC), forecasting a remarkable 20-fold increase in the company's revenue by 2030. This optimistic projection is underpinned by the escalating demand for computing power and a concurrent rise in the pricing power of 'neocloud' companies like iRhythm. In a September note, the bank upgraded IRTC from 'Underweight' to 'Overweight', signaling strong conviction in its future growth trajectory. Investors should monitor iRhythm's ability to capitalize on this burgeoning market, as the forecast suggests substantial upside potential.

  • 6/16/2026NEGATIVE
    iRhythm Investigates Cyber Incident After Hackers Claim Access To Sensitive Data

    iRhythm Technologies is investigating a cybersecurity incident where hackers claim to have accessed sensitive patient and proprietary data. The breach reportedly occurred via third-party applications. While the company states it does not foresee a material impact on its operations or finances, any data breach involving patient information can lead to regulatory scrutiny, reputational damage, and potential legal liabilities. Investors will monitor the situation closely for any further developments or undisclosed consequences that could affect the company's long-term prospects and stock valuation.

via Markets Gazette